Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23819192 | 1.00 | KMT2A (0.47) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL23844130 | 0.91 | KMT2A (0.54) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL26331473 | 0.85 | KMT2A (0.50) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL28854958 | 0.84 | CTSK (0.49) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL26277317 | 0.84 | CTSK (0.49) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL26288580 | 0.81 | SCN9A (0.37) | SCN9A | |
| SCHEMBL23819201 | 0.81 | KMT2A (0.41) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL32662642 | 0.80 | KMT2A (0.44) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL26331478 | 0.79 | KMT2A (0.44) | KMT2ACTSKCTSSCA1CA2 | |
| SCHEMBL26331475 | 0.77 | SCN9A (0.38) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2024-05-30 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4107164-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| EP-4106877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | KMT2A 3822/4885CTSK 1828/4885CTSS 1495/4885 |
| US-20220356196-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | KMT2A 3822/4885CTSK 1828/4885CTSS 1495/4885 |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | KMT2A 3816/4885CTSK 4185/4885CTSS 2261/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | KMT2A 3822/4885CTSK 1828/4885CTSS 1495/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | KMT2A 3822/4885CTSK 1828/4885CTSS 1495/4885 |
| US-20240174704-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | KMT2A 3822/4885CTSK 1828/4885CTSS 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.